Thursday, June 2, 2022

Regulus Therapeutics Names VP

San Diego-based biopharmaceuticals firm Regulus Therapeutics said today that it has named Amin Kamel, Ph.D., as Vice President, DMPK. The company said Dr. Kamel will support clinical development and advancement of its lead candidate, aimed at treating patients with autosomal dominant polycystic kidney disease (ADPKD). Kamel was most recently Scientific Director of Takeda, Drug Metabolism and Pharmacokinetics.